Calamos Advisors LLC Has $20.02 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Calamos Advisors LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 24.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 86,501 shares of the medical research company's stock after selling 28,715 shares during the period. Calamos Advisors LLC's holdings in IQVIA were worth $20,015,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. HF Advisory Group LLC increased its position in IQVIA by 7.8% during the 4th quarter. HF Advisory Group LLC now owns 6,975 shares of the medical research company's stock worth $1,614,000 after purchasing an additional 505 shares during the period. Daiwa Securities Group Inc. increased its stake in IQVIA by 12.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 34,983 shares of the medical research company's stock valued at $8,094,000 after purchasing an additional 3,908 shares in the last quarter. Telos Capital Management Inc. increased its stake in IQVIA by 0.6% in the 4th quarter. Telos Capital Management Inc. now owns 36,913 shares of the medical research company's stock valued at $8,541,000 after purchasing an additional 215 shares in the last quarter. HealthInvest Partners AB purchased a new position in IQVIA in the 4th quarter valued at approximately $2,392,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in IQVIA by 1.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,599 shares of the medical research company's stock valued at $18,418,000 after purchasing an additional 1,206 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IQV. UBS Group raised their price objective on IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a research note on Thursday, February 15th. Truist Financial raised their price objective on IQVIA from $286.00 to $297.00 and gave the company a "buy" rating in a research note on Tuesday, February 27th. Guggenheim cut IQVIA from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They set an "outperform" rating and a $290.00 target price on the stock. Finally, Robert W. Baird increased their target price on IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus target price of $256.80.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company's stock, valued at $199,610,278.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is owned by insiders.

IQVIA Trading Up 0.4 %

Shares of IQV stock traded up $0.92 during mid-day trading on Friday, hitting $228.09. 756,510 shares of the company's stock were exchanged, compared to its average volume of 966,570. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The stock has a 50-day simple moving average of $244.62 and a two-hundred day simple moving average of $221.41. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a market cap of $41.40 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.20 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.80 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The firm's revenue for the quarter was up 3.5% compared to the same quarter last year. Equities analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.